Glucokinase regulatory protein: Complexity at the crossroads of triglyceride and glucose metabolism

Current Opinion in Lipidology

Volumn 26, Issue 2, 2015, Pages 88-95

  Raimondo, Anne ^a   Rees, Matthew G ^b,c   Gloyn, Anna L ^a,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

diabetes therapy; glucokinase regulator; glucokinase regulatory protein; glucose homeostasis; hypertriglyceridaemia

Indexed keywords

GLUCOKINASE; GLUCOKINASE REGULATORY PROTEIN; GLUCOSE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CARRIER PROTEIN; ENZYME INHIBITOR;

BIOLOGICAL ACTIVITY; CRYSTAL STRUCTURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG TARGETING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HUMAN GENETICS; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; LIPID HOMEOSTASIS; LIPID METABOLISM; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NONHUMAN; PHENOTYPIC VARIATION; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; HOMEOSTASIS; METABOLISM; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY;

ANIMALS; CARRIER PROTEINS; DIABETES MELLITUS; ENZYME INHIBITORS; GLUCOSE; HOMEOSTASIS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; TRIGLYCERIDES;

EID: 84945295827     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000155     Document Type: Review

References (78)

1. Gloyn AL, Odili S, Buettger C, et al. Glucokinase and the regulation of blood sugar. In: Matschinsky FM, Magnuson MA, editors. Glucokinase and glycaemic disease: from basics to novel therapeutics. Basel: Karger 2004.
2. Van Schaftingen E. A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phosphate and fructose 1-phosphate. Eur J Biochem 1989; 179:179-184.
3. Detheux M, Vandercammen A, Van Schaftingen E. Effectors of the regulatory protein acting on liver glucokinase: a kinetic investigation. Eur J Biochem 1991; 200:553-561.
4. Vandercammen A, Detheux M, Van Schaftingen E. Binding of sorbitol 6-phosphate and of fructose 1-phosphate to the regulatory protein of liver glucokinase. Biochem J 1992; 286 (Pt 1):253-256.
5. Veiga-Da-Cunha M, Van Schaftingen E. Identification of fructose 6-phosphate-And fructose 1-phosphate-binding residues in the regulatory protein of glucokinase. J Biol Chem 2002; 277:8466-8473.
6. Orho-Melander M, Melander O, Guiducci C, et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 2008; 57:3112-3121.
7. Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316:1331-1336.
8. Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42:105-116.
9. Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009; 18:4081-4088.
10. Rees MG, Wincovitch S, Schultz J, et al. Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 2012; 55:114-122.
11. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-Density lipoprotein cholesterol, high-Density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008; 40:189-197.
12. Aulchenko YS, Ripatti S, Lindqvist I, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009; 41:47-55.
13. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466:707-713.
14. Johansen CT, Wang J, Lanktree MB, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010; 42:684-687.
15. Lange LA, Hu Y, Zhang H, et al. Whole-Exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet 2014; 94:233-245.
16. Peloso GM, Auer PL, Bis JC, et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56 000 whites and blacks. Am J Hum Genet 2014; 94:223-232.
17. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009; 41:56-65.
18. Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008; 40:161-169.
19. Vaxillaire M, Cavalcanti-Proenca C, Dechaume A, et al. The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 2008; 57:2253-2257.
20. Tam CH, Ma RC, So WY, et al. Interaction effect of genetic polymorphisms in glucokinase (GCK) and glucokinase regulatory protein (GCKR) on metabolic traits in healthy Chinese adults and adolescents. Diabetes 2009; 58:765-769.
21. Sparso T, Andersen G, Nielsen T, et al. TheGCKR rs780094 polymorphismis associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 2008; 51:70-75.
22. Li N, van der Sijde MR, Bakker SJ, et al. Pleiotropic effects of lipid genes on plasma glucose, HbA1c, and HOMA-IR levels. Diabetes 2014; 63:3149-3158.
23. Scott RA, Lagou V, Welch RP, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 2012; 44:991-1005.
24. Kamatani Y, Matsuda K, Okada Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 2010; 42:210-215.
25. Suhre K, Shin SY, Petersen AK, et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011; 477:54-60.
26. Saxena R, Hivert MF, Langenberg C, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010; 42:142-148.
27. Kettunen J, Tukiainen T, Sarin AP, et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 2012; 44:269-276.
28. Kolz M, Johnson T, Sanna S, et al. Meta-Analysis of 28 141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009; 5:e1000504.
29. Kottgen A, Pattaro C, Boger CA, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet 2010; 42:376-384.
30. Ridker PM, Pare G, Parker A, et al. Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Womens Genome Health Study. Am J Hum Genet 2008; 82:1185-1192.
31. Chambers JC, Zhang W, Sehmi J, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 2011; 43:1131-1138.
32. Lemaitre RN, Tanaka T, Tang W, et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-Analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet 2011; 7:e1002193.
33. Speliotes EK, Yerges-Armstrong LM,Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7:e1001324.
34. Gieger C, Radhakrishnan A, Cvejic A, et al. New gene functions in megakaryopoiesis and platelet formation. Nature 2011; 480:201-208.
35. Reiner AP, Beleza S, Franceschini N, et al. Genome-wide association and population genetic analysis of C-reactive protein in African American and Hispanic American women. Am J Hum Genet 2012; 91:502-512.
36. OSeaghdha CM, Wu H, Yang Q, et al. Meta-Analysis of genome-wide association studies identifies six new loci for serum calcium concentrations. PLoS Genet 2013; 9:e1003796.
37. Kraja AT, Chasman DI, North KE, et al. Pleiotropic genes for metabolic syndrome and inflammation. Mol Gen Metab 2014; 112:317-338.
38. Shin SY, Petersen AK, Wahl S, et al. Interrogating causal pathways linking genetic variants, small molecule metabolites, and circulating lipids. Genome Med 2014; 6:25.
39. Mahendran Y, Vangipurapu J, Cederberg H, et al. Association of ketone body levels with hyperglycemia and type 2 diabetes in 9398 Finnish men. Diabetes 2013; 62:3618-3626.
40. Nica AC, Ongen H, Irminger JC, et al. Cell-Type, allelic, and genetic signatures in the human pancreatic beta cell transcriptome. Genome Res 2013; 23:1554-1562.
41. Ferrannini E, Bjorkman O, Reichard GA Jr, et al. The disposal of an oral glucose load in healthy subjects. A quantitative study. Diabetes 1985; 34:580-588.
42. Mari A, Wahren J, DeFronzo RA, Ferrannini E. Glucose absorption and production following oral glucose: comparison of compartmental and arteriovenous-Difference methods. Metabolism 1994; 43:1419-1425.
43. Moore MC, Coate KC, Winnick JJ, et al. Regulation of hepatic glucose uptake and storage in vivo. Adv Nutr 2012; 3:286-294.
44. Toyoda Y, Miwa I, Kamiya M, et al. Evidence for glucokinase translocation by glucose in rat hepatocytes. Biochem Biophys Res Commun 1994; 204:252-256.
45. Toyoda Y, Miwa I, Kamiya M, et al. Tissue and subcellular distribution of glucokinase in rat liver and their changes during fasting-refeeding. Histochem Cell Biol 1995; 103:31-38.
46. Brown KS, Kalinowski SS, Megill JR, et al. Glucokinase regulatory protein may interact with glucokinase in the hepatocyte nucleus. Diabetes 1997; 46:179-186.
47. Farrelly D, Brown KS, Tieman A, et al. Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation. Proc Natl Acad Sci USA 1999; 96:14511-14516.
48. Agius L, Peak M, Van Schaftingen E. The regulatory protein of glucokinase binds to the hepatocyte matrix, but, unlike glucokinase, does not translocate during substrate stimulation. Biochem J 1995; 309 (Pt 3):711-713.
49. Grimsby J, Coffey JW, Dvorozniak MT, et al. Characterization of glucokinase regulatory protein-Deficient mice. J Biol Chem 2000; 275:7826-7831.
50. Zelent B, Raimondo A, Barrett A, et al. Analysis of the co-operative interaction between the allosterically regulated proteins GK and GKRP using tryptophan fluorescence. Biochem J 2014; 459:551-564.
51. Agius L, Peak M, Newgard CB, et al. Evidence for a role of glucose-induced translocation of glucokinase in the control of hepatic glycogen synthesis. J Biol Chem 1996; 271:30479-30486.
52. Rees MG, Ng D, Ruppert S, et al. Correlation of rare coding variants in the gene encoding human glucokinase regulatory protein with phenotypic, cellular, and kinetic outcomes. J Clin Invest 2012; 122:205-217.
53. Rees MG, Raimondo A, Wang J, et al. Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families. Hum Mol Genet 2014; 23:5570-5578.
54. Johansen CT, Wang J, Lanktree MB, et al. An increased burden of common and rare lipid-Associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2011; 31:1916-1926.
55. Lloyd DJ, St Jean DJ Jr, Kurzeja RJ, et al. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors. Nature 2013; 504:437-440.
56. Ashton KS, Andrews KL, Bryan MC, et al. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction. 1. Discovery of a novel tool compound for in vivo proof-of-concept. J Med Chem 2014; 57:309-324.
57. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009; 8:399-416.
58. Johnson D, Shepherd RM, Gill D, et al. Glucose-Dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator. Diabetes 2007; 56:1694-1702.
59. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003; 301:370-373.
60. Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-Treated patients with type 2 diabetes. Diabetes Care 2011; 34:2560-2566.
61. De Ceuninck F, Kargar C, Ilic C, et al. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 2012; 168:339-353.
62. Nissim I, Horyn O, Daikhin Y, et al. Effects of a glucokinase activator on hepatic intermediary metabolism: study with (13)C-isotopomer-based metabolomics. Biochem J 2012; 444:537-551.
63. Rees MG, Gloyn AL. Small molecular glucokinase activators: has another new antidiabetic therapeutic lost favour?. Br J Pharmacol 2013; 168:335-338.
64. Choi JM, Seo MH, Kyeong HH, et al. Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase. Proc Natl Acad Sci USA 2013; 110:10171-10176.
65. Beck T, Miller BG. Structural basis for regulation of human glucokinase by glucokinase regulatory protein. Biochemistry 2013; 52:6232-6239.
66. Pautsch A, Stadler N, Lohle A, et al. Crystal structure of glucokinase regulatory protein. Biochemistry 2013; 52:3523-3531.
67. Veiga-Da-Cunha M, Courtois S, Michel A, et al. Amino acid conservation in animal glucokinases. Identification of residues implicated in the interaction with the regulatory protein. J Biol Chem 1996; 271:6292-6297.
68. Brocklehurst KJ, Davies RA, Agius L. Differences in regulatory properties between human and rat glucokinase regulatory protein. Biochem J 2004; 378:693-697.
69. Veiga-Da-Cunha M, Sokolova T, Opperdoes F, Van Schaftingen E. Evolution of vertebrate glucokinase regulatory protein from a bacterial N-Acetylmuramate 6-phosphate etherase. Biochem J 2009; 423:323-332.
70. Baltrusch S, Francini F, Lenzen S, Tiedge M. Interaction of glucokinase with the liver regulatory protein is conferred by leucine-Asparagine motifs of the enzyme. Diabetes 2005; 54:2829-2837.
71. Baltrusch S, Lenzen S, Okar DA, et al. Characterization of glucokinasebinding protein epitopes by a phage-Displayed peptide library. Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel interaction partner. J Biol Chem 2001; 276:43915-43923.
72. Anderka O, Boyken J, Aschenbach U, et al. Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors. J Biol Chem 2008; 283: 31333-31340.
73. Vandercammen A, Van Schaftingen E. Competitive inhibition of liver glucokinase by its regulatory protein. Eur J Biochem 1991; 200:545-551.
74. Bourbonais FJ, Chen J, Huang C, et al. Modulation of glucokinase by glucose, small-molecule activator and glucokinase regulatory protein: steady-state kinetic and cell-based analysis. Biochem J 2012; 441:881-887.
75. Veiga-Da-Cunha M, Xu LZ, Lee YH, et al. Effect of mutations on the sensitivity of human beta-cell glucokinase to liver regulatory protein. Diabetologia 1996; 39:1173-1179.
76. Nishimura N, Norman MH, Liu L, et al. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction. 3.
77. St Jean DJ Jr, Ashton KS, Bartberger MD, et al. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction. 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles. J Med Chem 2014; 57:325-338.
78. Hong FT, Norman MH, Ashton KS, et al. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction. 4. Exploration of a novel binding pocket. J Med Chem 2014; 57:5949-5964.